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Management of retinoblastoma in older children (>5 years) using intra‑arterial
chemotherapy: Comparison of outcomes to prechemotherapy and intravenous
chemotherapy eras
Evan B Selzer, R Joel Welch, Pascal Jabbour1, Ann M Leahey2, Carol L Shields
Purpose: Intra‑arterial chemotherapy (IAC) has emerged as an effective treatment for retinoblastoma (RB)
however, little information exists regarding its use in older patients (>5 years). In the present study, we
evaluate the use of IAC (2008–2018) for RB in older patients and compare the outcomes to those in the
prechemotherapy (<1994) and intravenous chemotherapy (IVC) (1994–2007) eras. Methods: A retrospective
analysis of all patients older than 5 years treated with IAC for RB from 2008–2018. Comparisons were made
to 26 active RB cases in older children treated in the prechemotherapy era and to 12 active RB cases treated
in the IVC era. Results: There were 13 eyes with RB in 13 older patients treated in the IAC era. The median
patient age was 6.8 years. Tumor response was achieved in all 13 eyes at a median interval of 1.1 months from
first IAC. Globe salvage was achieved in eight eyes with five eyes requiring enucleation. At 14 months, median
follow‑up after IAC, there was no metastasis or death. Compared to the prechemotherapy era, those in the IAC
era demonstrated significant reduction in need for enucleation (P < 0.001) and EBRT or enucleation (P < 0.001).
Compared to the IVC era, there was significant reduction in need for EBRT (P = 0.02) and EBRT or
enucleation (P = 0.03) and similar avoidance of metastasis (P > 0.99) and death (P > 0.99). Conclusion: Older
patients with RB managed in the IAC era demonstrated reduced need for EBRT or enucleation compared to
those managed in the IVC or prechemotherapy eras, with no instance of metastasis or death.
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A majority (95%) of retinoblastoma (RB) cases occur in children
under the age of 5 years; however, RB can be present in older
children and even manifest in adults, with the oldest published
patient demonstrating newly diagnosed RB at 74 years of age.[1‑8]
Older children and adults with newly diagnosed RB tend to
present with more disease, often requiring enucleation. In a
literature search of 45 published cases of adult‑onset RB from
1919 to 2015, globe salvage was achieved in only two cases (4%).[1]

Board of the Wills Eye Hospital, Philadelphia, Pennsylvania.
All patients from the ocular oncology service with RB and
age ≥5 years were reviewed. Those treated with IAC as a
primary or secondary measure were selected for analysis.
Patients less than 5 years of age were excluded from the study.
This analysis was compliant to the tenets of the Declaration of
Helsinki and was approved by the Institutional Review Board
of the Wills Eye Hospital, Philadelphia, Pennsylvania.

The efficacy and safety of intra‑arterial chemotherapy (IAC)
have been established in several studies; [9‑16] revealing
approximately 67% globe salvage even with advanced eyes and
minimal local toxicity to the globe, especially in recent years,
as published from our center and others.[14‑16] However, little
information is available on the results of IAC for older children and
adults. In this retrospective analysis, we explore the use of IAC for
RB in older patients and compare results to previously published
reports representing data from the prechemotherapy era (<1994)[2]
and the intravenous chemotherapy (IVC) era (1994–2007).[17]

All patients were examined under anesthesia when
necessary, using indirect ophthalmoscopy and fundus details
were documented using large fundus drawings, external
photography, wide‑angle fundus photography, fluorescein
angiography, B‑scan ultrasonography, and optical coherence
tomography. The procedure for IAC has been described
elsewhere.[9,10]

Methods
This analysis was compliant to the tenets of the Declaration
of Helsinki and was approved by the Institutional Review
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Recorded data included age at diagnosis, race, sex, symptom,
hereditary pattern of RB (familial, sporadic), affected eye (right,
left, both), age at treatment, and visual acuity. Each eye was
classified according to the International Classification for
International Classification for Retinoblastoma (ICRB).[18,19] Each
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tumor was evaluated for largest basal dimension, thickness,
proximity to the optic disc, and foveola (in mm), associated
subretinal or vitreous seeds, macular subretinal fluid, and
anterior segment tumor. Treatment with IAC was characterized
by a number of cycles, agents used (melphalan, topotecan,
carboplatin), and cumulative dose. Additional treatments
including intravitreal chemotherapy, IVC, plaque radiotherapy,
and external beam radiation therapy (EBRT) were noted. After
each cycle of IAC, tumor response was observed clinically
and documented photographically and ultrasonographically.
Visual acuity following treatment was documented.
Comparisons to historical data were performed to evaluate
differences in the need for EBRT, enucleation, EBRT or
enucleation, and the development of metastasis and death.
All 13 cases were compared to 26 active RB cases in older
children treated in the prechemotherapy era,[2] and 10 of the
13 cases (those with unilateral RB only) were compared to 12
active unilateral RB cases in a series treated with IVC.[17] Data
were compiled in Microsoft Excel (2016) and measures of
central tendency were calculated. Statistical comparisons were
made using a two‑sided Fisher’s exact test. P values < 0.05 were
considered statistically significant.

Results
In this study, there were 13 eyes with RB in 13 older
patients (>5 years) that received IAC. Patient demographic
and clinical features are listed in Table 1. The median patient
age at the time of IAC was 6.8 years (mean 10.1, range
5.2‑32.3 years). The patients were male (7/13, 54%) and
white (11/13, 84%). The median visual acuity on presentation
was 20/100 (mean 20/400, range 20/20‑light perception (LP)).
Patients presented a median of 1 tumor per eye (mean 1.5,
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range 1–8). The eyes were classified as either group D (n = 9,
69%) or group E (n = 4, 31%) according to ICRB [Fig. 1]. Three
patients had bilateral RB, but only one eye was treated with
IAC in each case.
The median largest basal tumor dimension was 16 mm (mean
15.2, range: 7–24 mm) with a median thickness of 7 mm (mean 7,
range 3–14 mm) as measured by ultrasonography. Tumors were
a median of 2 mm from the foveola (mean 3.5, range 0–9 mm)
and 3 mm from the optic disc (mean 3.6, range 0–10 mm).
Vitreous seeding was present in 12 patients (92%), subretinal
seeding in six patients (46%), and no view of the retina in three
patients (23%). Anterior segment seeding was present in three
patients (23%).
Treatment and outcomes are listed in Table 2. Intra‑arterial
chemotherapy was primary therapy (n = 8, 62%) or secondary
therapy (n = 5, 38%). Previous treatments included IVC (n = 4),
plaque radiotherapy (n = 1), intravitreal chemotherapy (n = 1),
or EBRT (n = 1). The median number of IAC cycles was 3 (mean
3.6, range 2–7 cycles). A median cumulative dose of 20 mg of
melphalan (mean 19.6, range 10–45 mg), 3 mg topotecan (mean
2.6, range 1–4 mg), and 0 mg of carboplatin (mean 9.2 mg,
range 0–120 mg).
Initial tumor response was observed in all 13 eyes at a median
interval of 1.1 months (mean 1.3, range 0.9–2.3 months) [Fig. 1].
The globe was salvaged in eight eyes (62%) and enucleation was
necessary in five eyes (38%) for reasons of recurrence of solid
tumor (n = 2), vitreous seeds (n = 2), or subretinal seeds (n = 1).
Two of the three eyes with anterior segment seeding were
enucleated due to recurrent seeding. There was no instance of
metastasis or death after a median follow‑up of 14 months. Of
the eight eyes in which globe salvage was achieved, the median
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Figure 1: Retinoblastoma in older children. A 71‑month‑old female with unilateral leukocoria (a) and funduscopy (b) demonstrating a large group D
retinoblastoma. Following six cycles of intra‑arterial chemotherapy and six intravitreal chemotherapy injections, (c) the tumor demonstrated
rapid reduction, but recurrent subretinal seeds lead to enucleation per parent request. An 81‑month‑old female with unilateral leukocoria (d) and
funduscopy (e) demonstrating a large group E retinoblastoma. Following four cycles of intra‑arterial chemotherapy and six intravitreal chemotherapy
injections, (f) tumor control was achieved with ultimate globe salvage
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Table 1: Intra‑arterial chemotherapy (IAC) for retinoblastoma in older patients (>5 years): Patient demographics and
clinical features at the time of IAC
Number (%), n=13 eyes, 13 patients

Features
Median age at RB diagnosis, years (mean, range)

6.7 (9.4, 2.5‑28.9)*

Median age at IAC, years (mean, range)

6.8 (10.1, 5.2‑32.3)

Sex
Male
Female

7 (54)
6 (46)

Race
White
Black
Asian

11 (84)
1 (8)
1 (8)

Laterality
Unilateral RB
Bilateral RB

10 (77)
3 (23)

Eye treated with IAC, n=13 eyes
Right eye
Left eye

10 (77)
3 (23)

ICRB group of the eye treated with IAC
A
B
C
D
E

0 (0)
0 (0)
0 (0)
9 (69)
4 (31)

Visual acuity at IAC, median (mean, range)

20/100 (20/400, 20/20‑LP)

Number of tumors per eye, median (mean, range)

1 (1.5, 1‑8)

Median largest basal diameter, mm (mean, range)

16 (15.2, 7‑24)

Median thickness by ultrasound, mm (mean, range)

7 (7.0, 3‑14)

Median distance to fovea, mm (mean, range)

2 (3.5, 0‑9)

Median distance to optic disc, mm (mean, range)

3 (3.6, 0‑10)

Vitreous seeding
Present
Absent

12 (92)
1 (8)

Subretinal seeding
Present
Absent
No view
Anterior segment seeding
Present
Absent

6 (46)
4 (31)
3 (23)
3 (23)
10 (77)

*One patient was diagnosed at age 2.5 years and treated with systemic chemotherapy and plaque radiation; he was not treated with IAC until age 5.8 years.
IAC=Intra‑arterial chemotherapy; RB=Retinoblastoma; ICRB=International Classification of Retinoblastoma; mm=millimeter

visual acuity was 20/400 (mean: 20/400, range 20/30‑light
perception). Each patient course is listed in Table 3.

was no difference in prevention of metastasis (P > 0.99) or
death (P > 0.99).

In Table 4, a comparison of these 13 older patients with
RB managed with IAC versus 26 older patients with active
RB treated in the prechemotherapy era is listed. Patients
treated with IAC demonstrated a significant reduction
in need for enucleation (P value <0.001) and EBRT or
enucleation (P < 0.001), along with insignificant reductions
in the need for EBRT (P = 0.07). There was no difference in
prevention of metastasis (P = 0.28) or death (P = 0.28).

Discussion

In Table 5, a comparison of 10 older patients with unilateral
RB treated with IAC versus 12 older patients with unilateral
RB (Reese‑Ellsworth group V) treated with IVC is listed. There
was significant reduction in need for EBRT (P‑value = 0.02)
and EBRT or enucleation (P = 0.03) in those treated with
IAC, insignificant reduction in enucleation (P = 0.23). There

There have been few published series on the topic of RB in
older children.[1‑8] In most series, management was enucleation
for all subjects.[1‑8] The largest published series of RB in older
patients revealed enucleation in 24 out of 26 cases (92%),[2]
and a review of published case reports and case series
revealed enucleation in 43 of 45 cases (96%).[1] In those large
cohorts, metastases occurred in 15% and death in 7%.[1,2] An
additional comprehensive study in 1986, on the effect of age at
diagnosis of RB on patient survival in 1147 patients, revealed
retinoblastoma‑related mortality for young patients (0–1 years)
was 4.6%, for intermediate age patients (1–2 years) was 8.9%,
for older patients (2–7 years) was 19%, and for the oldest
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Table 2: Intra‑arterial chemotherapy (IAC) for retinoblastoma in older patients (>5 years): Treatments and outcomes
Features
Type of IAC treatment
Primary
Secondary

Number (%), n=13 eyes
8 (62)
5 (38)

Treatment before IAC
None
IVC
IVT
External beam radiotherapy
Plaque*

8
4
1
1
1

Treatments following initial IAC
None
IVT
Enucleation
IVT + enucleation
IVT + plaque
IVT + plaque + enucleation

2
5
2
2
1
1

Total number of IAC cycles, median (mean, range)
Cumulative melphalan dose, mg, median (mean, range)
Cumulative topotecan dose, mg, median (mean, range)
Cumulative carboplatin dose, mg, median (mean, range)†
Total number of IVT injections, median (mean, range)
Cumulative melphalan dose, µg, median (mean, range)
Cumulative topotecan dose, µg, median (mean, range)
Initial tumor response achieved

3 (3.6, 2‑7)
20 (19.6, 10‑45)
3 (2.6, 1‑4)
0 (9.2, 0‑120)
4 (3.8, 0‑6)
92.5 (79.2, 0‑145)
0 (28.3, 0‑120)
13 (100)

Median time to tumor response after initial IAC, months (mean, range)

1.13 (1.26, 0.90‑2.33)

Median length of follow‑up after IAC, months (mean, range)

13.8 (16.5, 1.9‑39.8)

Enucleation

5 (38)

Metastasis
Death

0 (0)
0 (0)

IAC=Intra‑arterial chemotherapy; IVC=Intravenous chemotherapy; IVT=Intravitreous chemotherapy; Plaque=Radioactive iodine brachytherapy with tumor apex
dose of 35 Gy; *This patient received 3 plaques prior to IAC with tumor apex doses of 40 Gy, 40 Gy, and 35 Gy; mg=Milligram; †Carboplatin used in a single
case; µg=Microgram; HM=Hand motions; LP=light perception

patients (7 years) was 2%.[20] Since the publication of that report
33 years ago, survival has improved conclusively.[21]
More recently, we and others have employed IAC for
moderate to advanced RB, particularly in patients with
unilateral disease. [9‑14,21,22] In a cohort of 70 eyes with RB
managed with IAC in patients of all ages; we achieved complete
tumor control with globe salvage in 72% of those treated
primarily and 62% of those treated secondarily (after the failure
of other treatments).[13] In that series, none of the patients
developed metastatic disease or had a serious adverse event
such as cerebrovascular accident, despite catheterization of the
internal carotid artery. An international collaborative effort
from six major RB centers, including ours, evaluating 1177 eyes
of 1139 patients with RB managed with IAC found metastatic
disease and death in three patients (<1%), all treated in South
America and with difficulty in follow‑up.[22] This compelling
evidence provides the support that IAC can adequately control
RB with little risk for metastasis and death.
In this analysis, we evaluated a unique subset of patients
older than the age of 5 years to explore if IAC provided
adequate control for this older cohort. At a median of 14 months
follow‑up, we found compelling evidence that IAC was safe
and effective for these patients, with the need for additional
EBRT in no case, enucleation in 5 cases, and metastasis and

death in no case. The patients in this series had advanced RB
with ICRB group D (n = 9) or E (n = 4) as is typical in older
patients presenting with RB.
Further, comparison of this older cohort managed in
the IAC era (2008‑2018) versus a similar cohort managed
in the prechemotherapy era (<1994) revealed significant
reduction in the need for enucleation (P value <0.001) and
EBRT or enucleation (P < 0.001). Moreover, comparison of
those in the IAC era to those in the IVC era (1994‑2007),
revealed significant reduction in EBRT (P = 0.02) and
EBRT or enucleation (P = 0.03), and similar prevention of
metastasis (P > 0.99) and death (P > 0.99). Both of these
comparisons support our observations that IAC is more
effective than IVC or older methods in avoiding EBRT and/or
enucleation, without risking tumor‑related metastasis.
There are limitations to our analysis as we realize that these
older patients are from published cohorts at different eras,
and staging and treatment strategies have evolved over time.
In addition, our evaluation of RB in older children during
the IAC era included only those selected for IAC, while there
were others who were managed with enucleation, deemed
not suitable for IAC. Furthermore, our comparison of IAC
to IVC for unilateral RB included all ages and might not be
directly comparable to our older children described herein.
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3
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0
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0
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4
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of IVT
injections

IVT
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Enucleation
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Metastasis/
Death

8.1
71.0

10.3

1.9

39.9

12.9

17.1

22.7

15.0

74.5

11.3

5.0
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Total
follow
up (mo)

Outcomes
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20/30

20/400

20/400
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Enuc

Enuc*

20/200

NA

Enuc

Visual
acuity at last
follow up

*Received plaque after initiation of IAC, prior to enucleation; IAC=intraarterial chemotherapy; IVT=intravitreal chemotherapy; Uni=unilateral; Bi=bilateral; ICRB=international classification of retinoblastoma;
mg=milligram; mo=month; LP=light perception; HM=hand motions; F and F=fix and follow; EBRT=external beam radiotherapy; IVC=intravenous chemotherapy (systemic chemotherapy); Plaque=radioactive iodine
brachytherapy; NA=not available; Enuc=enucleation
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Table 3: Summary of demographics, treatment, and outcomes in 13 older patients (>5 years) with retinoblastoma treated with intra‑arterial chemotherapy (IAC)
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Table 4: Outcomes of retinoblastoma management in older children (>5 years) in the intra‑arterial chemotherapy (IAC) era
(2008‑2018) vs. the prechemotherapy era (<1994)
Prechemotherapy era* <1994 n=26

IAC era 2008‑2018 n=13

Need for EBRT, no. (%)
EBRT
No EBRT

7 (27%)
19 (73%)

0 (0%)
13 (100%)

Need for enucleation, no. (%)
Enucleation
No enucleation

24 (92%)
2 (8%)

5 (38%)
8 (62%)

Need for EBRT or Enucleation, no. (%)
EBRT or Enucleation
No EBRT or Enucleation

26 (100)
0 (0)

5 (38%)
8 (62%)

4 (15%)
22 (85%)

0 (0%)
13 (100%)

4 (15%)
22 (85%)

0 (0%)
13 (100%)

Outcome

Development of Metastasis, no. (%)
Metastasis
No Metastasis
Development of Death, no. (%)
Death
No Death

P
0.07

<0.001

<0.001

0.28

0.28

*Data from Shields Cl, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology1991;98 (3):395‑399; EBRT=External beam radiotherapy

Table 5: Outcomes of retinoblastoma management in older children (>5 years) in the intra‑arterial chemotherapy (IAC) era
(2008‑2018) vs. the intravenous chemotherapy (IVC) era (1994‑2007)
IVC era* 1994‑2007 n=12

IAC era 2008‑2018 n=10†

Need for EBRT, no. (%)
EBRT
No EBRT

6 (50%)
6 (50%)

0 (0%)
0 (0%)

Need for enucleation, no. (%)
Enucleation
No enucleation

7 (58%)
5 (42%)

3 (30%)
7 (70%)

Need for EBRT or Enucleation, no. (%)
EBRT or Enucleation
No EBRT or Enucleation

10 (83%)
2 (17%)

3 (30%)
7 (70%)

0 (0%)
12 (100%)

0 (0%)
10 (100%)

0 (0%)
0 (100%)

0 (0%)
10 (100%)

Outcome

Development of Metastasis, no. (%)
Metastasis
No Metastasis
Development of Death, no. (%)
Death
No Death

P
0.02

0.23

0.03

>0.99

>0.99

*Twelve patients with Reese‑Ellsworth group V retinoblastoma. Data from Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma.
Arch Ophthalmol 2002;120 (12):1653‑1658; †Only the 10 cases of unilateral RB from this series were used in this comparison; EBRT=External beam radiotherapy

However, it has been shown that RB in older children tends to
be more advanced with greater risk for metastasis and death.[20]
The globe salvage and survival rates in this study cannot
be attributed solely to IAC, as IVT and prior therapies are
equally contributory. In addition, longer follow‑up regarding
metastasis and death is preferred and our study is limited by
a relatively short follow‑up interval.

Conclusion
In summary, we present 13 cases of RB in older children
treated with IAC and with ultimate globe salvage in 62%
and with no evidence of metastasis or death. Despite most
eyes having advanced disease, IAC was safe and effective.
Furthermore, comparisons to similar cohorts treated in the
prechemotherapy and IVC eras suggested a reduction in
need for additional EBRT and/or enucleation. We advise
that selected older children with RB could be managed
successfully with IAC.
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therapy. Retinoblastoma in older patients presents with some
unique challenges – these are advanced tumors, more often
requiring enucleation, the threshold for enucleation being
lower considering that older patients are more likely to have
unilateral disease. An advanced, unilateral retinoblastoma is
more often primarily enucleated in contrast to a bilateral disease
wherein one would attempt some form of chemotherapy with
the aim to salvage at least one of the eyes, eventually ending up
with salvaging both eyes in a significant number of patients.
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The authors of this study did not find metastasis or death in
the 13 patients treated with IAC. One, however, has to note that
the mean follow‑up is only 14 months, limiting the validity of
this observation from this study, but the large volume of data
on IAC from other studies also do not show increased risk of
metastasis or death.
Bilateral retinoblastoma usually presents early. It is of
note that three patients in this series had bilateral disease,
but presented after 5 years of age. While rare, occurrence
of bilateral disease has been reported in older children by
other authors as well.[2] This reiterates the fact that even if
a child were to present with retinoblastoma, later in life, it
is imperative that both eyes are carefully examined looking
for the presence of bilateral disease, thereby the genetic
implications of the disease.
IAC has become the first choice of treatment to treat
retinoblastoma in developed nations. It avoids systemic
complications of IVC, which may require expensive
hospitalization to manage them at the cost of significant
morbidity as well. The technique of IAC may be relatively easier

